Company Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States.
The company’s lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom’s macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin’s lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.
It also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors.
It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
| Country | United States |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | James Caruso |
Contact Details
Address: 100 Campus Drive Florham Park, New Jersey 07932 United States | |
| Phone | 608 441 8120 |
| Website | cellectar.com |
Stock Details
| Ticker Symbol | CLRB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001279704 |
| CUSIP Number | 15117F500 |
| ISIN Number | US15117F8077 |
| Employer ID | 04-3321804 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| James V. Caruso | President, Chief Executive Officer and Director |
| Chad J. Kolean CPA | Vice President, Chief Financial Officer and Secretary |
| Jarrod Longcor | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 17, 2025 | 8-K | Current Report |
| Mar 13, 2025 | 8-K | Current Report |
| Mar 13, 2025 | 10-K | Annual Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Feb 7, 2025 | 424B3 | Prospectus |
| Feb 6, 2025 | EFFECT | Notice of Effectiveness |
| Feb 3, 2025 | UPLOAD | Filing |
| Feb 3, 2025 | SCHEDULE 13G/A | Filing |